Chembio Diagnostics, Inc. 20% upside target

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The firm expanding its product portfolio based upon the proprietary Dual Path Platform, which uses a small drop of blood from the fingertip to provide cost-effective diagnostic results in approximately 15 minutes. Its products include human and veterinary diagnostics. The company was founded in 1985 and is headquartered in Hauppauge, NY.